Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

IPCALAB's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 2.568000
forwardPE 27.142687
debtToEquity 14.425000
earningsGrowth 0.365000
revenueGrowth 0.086000
grossMargins 0.663150
operatingMargins 0.172730
trailingEps 32.770000
forwardEps 53.892970

Ipca Laboratories Limited's current ratio of 2.568 highlights the company's solid liquidity, indicating that it can easily service its short-term debt. Ipca Laboratories Limited's ample cash reserves and current assets ensure that the company is well-positioned to meet its immediate financial liabilities.
Ipca Laboratories Limited's Forward PE is in a reasonable range, indicating the stock is priced well relative to its earnings. The stock isn't overpriced, which leaves room for future growth, making it an attractive option for investors seeking value and long-term gains.
IPCALAB's low Debt-to-Equity ratio indicates that the company isn't heavily dependent on debt financing. This lower leverage reduces financial risk and enhances stability, showing that IPCALAB is well-positioned to manage its obligations without the burden of excessive debt.
IPCALAB's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that IPCALAB's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

Ipca Laboratories Limited's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about Ipca Laboratories Limited's ability to generate strong results going forward.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


2 sales transactions of IPCALAB were conducted, with market price at 1465.7999877929688.There were no sell transactions during the period under consideration.More recent purchases than sales at current price levels for Ipca Laboratories Limited could signal growing investor confidence. This buying trend might suggest that market sentiment is leaning toward a positive outlook for the stock, possibly indicating expectations of favorable performance in the near future.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Analysts have shown a buy bias for Ipca Laboratories Limited, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to Ipca Laboratories Limited, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.